Literature DB >> 18023572

State of the art and recent advance in the treatment of resectable nonmetastatic rectal cancer.

C Ortholan1, J P Gerard, K Benezery, E Francois.   

Abstract

INTRODUCTION: Standard treatment is achieving good local control for rectal cancer. Innovative approach is aiming at increasing conservative treatment.
METHODOLOGY: Strong evidence relies on randomized trials. Phase I and II trials are the method to evaluate advances.
RESULTS: Preoperative radiotherapy with concurrent chemotherapy is the standard treatment for most of the T3 (4) tumors. To increase conservative treatment innovative neoadjuvant treatment achieving complete clinical response is a promising approach.
CONCLUSION: Well-conducted clinical trials are improving the standard treatments and are evaluating new hypotheses.

Entities:  

Mesh:

Year:  2007        PMID: 18023572     DOI: 10.1016/j.suronc.2007.10.023

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  1 in total

1.  Medical oncology: Multimodality therapy in unresectable colorectal cancer.

Authors:  Daniel A Popowich; Amy L Halverson
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.